Neurology: Volume 97, Number 7, August 17, 2021 Exam #1 - Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity

About this course

  • Released: 08/17/2021
  • Expires: 08/17/2024

PROSPECTIVE EVALUATION OF HEALTH CARE PROVIDER AND PATIENT ASSESSMENTS IN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROTOXICITY

LEARNING OBJECTIVES:

Upon completion of the article by Alberti et al, the participant should be able to:
  • State the proportion of patients in this study with a normal neurologic exam initially who developed neuropathy during a course of chemotherapy treatment, as assessed by the Total Neuropathy Score – clinical version (TNSc)
  • Discuss the observed correlation between neuropathy assessments obtained by TNSc and those obtained by the Total Neuropathy Score – nurse assessed version (TNSn) in this study
  • Describe how patient-reported symptoms of chemotherapy-induced neurotoxicity were associated with scores on the TNSc and TNSn in this study

CORE COMPETENCIES:

The article by Alberti et al covers the following core competency:
  • Medical Knowledge

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.

 

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm) have no disclosures.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME